Algernon declares reduction of key fibrosis marker in a NASH study
Category: #health  By Pankaj Singh  Date: 2019-04-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Algernon declares reduction of key fibrosis marker in a NASH study

The company’s conducted biochemical analysis depicted that neither NP-135 or Cenicriviroc (CVC) showed any major negative effect on any vital metabolic markers.

Algernon Pharmaceuticals Inc., a Canada-based clinical stage pharmaceutical company, has reportedly announced that following additional biochemical analysis, one of the lead compounds for NASH (non-alcoholic steatohepatitis), known as NP-135, demonstrated a reduction of about 34.6 percent of a key secondary marker of fibrosis & liver hydroxyproline, besides being metabolically neutral in several significant measurements.

The analysis, for the uninitiated, was an integral part of a pre-clinical NASH study that was recently completed and which deployed the widely recognized STAM™ mouse model from the SMC Laboratories.

Christopher J. Moreau, the Chief Executive Officer at Algernon Pharmaceuticals, was reportedly quoted saying that the common problematic issue in NASH as well as other relevant diseases is fibrosis. He went on to elaborate that the company strongly believes NP-135 to soon become a leading candidate for NASH’s management and treatment, solely on account of the fact that NP-135 has been observed to have directly reduced fibrosis in the NASH study by about 84.3 percent, while further reducing hydroxyproline (another significant marker), by around 34.6 percent as well.

If sources familiar with the matter are to be believed, the results from the biochemical analysis showed that neither NP-135 nor CVC (Cenicriviroc) – which are both a positive control & comparator arm in the NASH study and currently in its Phase III trials – demonstrated any negative impact on any significant metabolic markers such as lipids, glucose and cholesterol. Sources further added that NP-135 (22mg per kg) highlighted a 34.6 percent reduction (which is p<0.001) in liver hydroxyproline, while Cenicriviroc (40 mg per kg) showed a 29 percent reduction (which is p<0.01) in the same, when compared to negative controls.

For the record, Algernon Pharmaceuticals is recognized for its emphasis on the advancement of lead compounds for NASH, IBD (Inflammatory Bowel Disease) and CKD (Chronic Kidney Disease).



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...